Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01939054 |
|
Recruitment Status : Unknown
Verified June 2015 by Binghe Xu, Chinese Academy of Medical Sciences.
Recruitment status was: Recruiting
First Posted : September 11, 2013
Last Update Posted : June 4, 2015
|
Sponsor:
Chinese Academy of Medical Sciences
Collaborator:
Biotech Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Binghe Xu, Chinese Academy of Medical Sciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | September 2015 |
| Estimated Study Completion Date : | September 2016 |